Topiramate augmentation in a patient with obsessive-compulsive disorder.
From the MacAnxiety Research Centre, McMaster University, and Hamilton Health Sciences, Hamilton, Ont., Canada.
Michael
M
Van Ameringen
From the MacAnxiety Research Centre, McMaster University, and Hamilton Health Sciences, Hamilton, Ont., Canada.
Beth
B
Patterson
D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D015283:Citalopram / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D005239:Fear / Q000187:drug effects*; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000627:therapeutic use; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D017374:Paroxetine / Q000627:therapeutic use; D012008:Recurrence; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use; D000077236:Topiramate; D016312:Treatment Refusal
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D015283:Citalopram; D005632:Fructose; D008140:Lorazepam; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000077236:Topiramate